Zepp Health Corporation
NYSE:ZEPPConsumer Electronics
-$0.03 today
- Market cap
- $50.84M
- Beta
- 1.78
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$282.07
Volume 0.04M
Average 0.13M
ZEPP Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Zepp Health CorporationNYSE: ZEPP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was CN¥0, compared with CN¥0 a year earlier. Trailing-twelve-month depreciation & amortization was CN¥14.04M. Over 3 fiscal years it compounded at -19.0% a year.
Context
- Depreciation & amortization amounted to 1.7% of revenue in FY2025, down 1.0 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near CN¥0 or moves back toward the trailing-twelve-month quarterly average of CN¥3.51M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
CNY · from the income statement
- Latest · FY2025
- 31.71M CNY
- Year-over-year change
- -13.4%
- 4-year CAGR
- -11.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.71M | -13.4% |
| FY2024 | 2024-12-31 | 36.64M | -32.7% |
| FY2023 | 2023-12-31 | 54.43M | -8.7% |
| FY2022 | 2022-12-31 | 59.65M | +16.5% |
| FY2021 | 2021-12-31 | 51.21M | — |
Depreciation & Amortization vs competitors
How ZEPP compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +240.5% is the highest of 8, against a peer median of -0.8%.
- Depreciation & amortization amounts to 0.7% of revenue for ZEPP, versus a peer median of 6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $88.37M USD | -7.5% | -7.1% | 4.2% | |
| LTM Mar 2026 | $48.17M USD | +6.6% | +3.1% | 31.5% | |
| LTM Mar 2026 | CN¥14.04M CNY | +240.5% | -19.0% | 0.7% | |
| LTM Mar 2026 | $10.16M USD | -29.1% | -25.0% | 1.5% | |
| LTM Mar 2026 | $6.97M USD | -5.5% | +11.8% | 5.0% | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $4.31M USD | +168.6% | +84.7% | 6.5% |
| FY2025 | $2.29M USD | +4.0% | +5.2% | 13.4% | |
| LTM Mar 2026 | $1.41M USD | -0.8% | +75.3% | 7.6% | |
| Peer median (excluding ZEPP) | — | -0.8% | +5.2% | 6.5% | |
Competitors are the stored peer set for ZEPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.17B | 4.22B | 2.5B | 1.33B | 1.82B |
| Cost of Revenue | 4.88B | 3.4B | 1.84B | 820.57M | 1.1B |
| Gross Profit | 1.29B | 817.22M | 653.7M | 512.88M | 711.63M |
| Gross Margin | 20.9% | 19.4% | 26.2% | 38.5% | 39.2% |
| Research & Development | 508.41M | 526.2M | 364.53M | 337.07M | 317.73M |
| Selling, General & Admin | 687.6M | 708.46M | 504.69M | 520.85M | 582.64M |
| Operating Expenses | 1.2B | 1.23B | 869.22M | 857.92M | 916.56M |
| Depreciation & Amortization | 51.21M | 59.65M | 54.43M | 36.64M | 31.71M |
| EBITDA | 200.8M | (261.43M) | (142.88M) | (345.66M) | (191.48M) |
| EBITDA Margin | 3.3% | -6.2% | -5.7% | -25.9% | -10.5% |
| Operating Income | 92.73M | (417.45M) | (215.52M) | (345.04M) | (204.93M) |
| Operating Margin | 1.5% | -9.9% | -8.6% | -25.9% | -11.3% |
| Interest Income | 16.47M | 12.55M | 21.86M | 26.81M | 10.7M |
| Interest Expense | 44.3M | 58M | 47.79M | 40.54M | 39.94M |
| Other Income / Expenses | 53.06M | 56.34M | (21.7M) | (108.55M) | (58.2M) |
| Income Before Tax | 145.78M | (361.11M) | (237.22M) | (453.59M) | (263.13M) |
| Pre-Tax Margin | 2.4% | -8.6% | -9.5% | -34.0% | -14.5% |
| Income Tax Expense | 10.61M | (67.03M) | (17.2M) | 99.99M | 17.79M |
| Net Income | 136.02M | (293.37M) | (220.49M) | (554.13M) | (280.92M) |
| Net Margin | 2.2% | -7.0% | -8.8% | -41.6% | -15.5% |
| EPS (Basic) | 1.38 | (2.71) | (1.96) | (34.16) | (283.04) |
| EPS (Diluted) | 1.31 | (2.71) | (1.96) | (34.16) | (283.04) |
| Weighted Avg Shares | 15.76M | 15.39M | 15.2M | 16.18M | 993.87K |
| Weighted Avg Shares (Diluted) | 16.52M | 15.39M | 15.2M | 16.18M | 993.87K |
Zepp Health Corporation
NYSE:ZEPP
Intrinsic Alpha fair value
Locked
Current Price
$3.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.